Document is current
Any future updates will be listed below
-
Authors
Gallage, Suchira https://orcid.org/0000-0002-1956-3597
Avila, Jose Efren Barragan https://orcid.org/0000-0002-9348-909X
Ramadori, Pierluigi
Focaccia, Enrico https://orcid.org/0000-0001-9913-3492
Rahbari, Mohammad https://orcid.org/0000-0003-1133-2134
Ali, Adnan
Malek, Nisar P.
Anstee, Quentin M. https://orcid.org/0000-0002-9518-0088
Heikenwalder, Mathias https://orcid.org/0000-0002-3135-2274
- License Information
-
More Information
Article History
Received: 10 May 2022
Accepted: 26 October 2022
First Online: 20 December 2022
Competing interests
: Q.M.A. is coordinator of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the Innovative Medicines Initiative (IMI2) Program of the European Union under grant agreement 777377. This multi-stakeholder consortium includes industry partners and received funding from EFPIA. Q.M.A. received funding from AstraZeneca, Boehringer Ingelheim, Intercept and royalties from Elsevier. Q.M.A. received consulting fees on behalf of Newcastle University from Alimentiv, Akero, AstraZeneca, Axcella, 89Bio, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, Genfit, Genentech, Gilead, GlaxoSmithKline, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGMBio, Novartis, Novo Nordisk, PathAI, Pfizer, Poxel, Resolution Therapeutics, Roche, Ridgeline Therapeutics, RTI, Shionogi and Terns. Q.M.A. received fees for lectures from Fishawack, Integritas Communications, Kenes, Novo Nordisk, Madrigal, Medscape and Springer Healthcare. The other authors declare no competing interests.
